EAM
VERV

Erste Asset Management’s Verve Therapeutics VERV Stock Holding History

Erste Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,300
Closed -$56.3K – 573
2024
Q3 		$56.3K Hold
11,300
– – ﹤0.01% 508
2024
Q2 		$53.8K Hold
11,300
– – ﹤0.01% 507
2024
Q1 		$149K Hold
11,300
– – ﹤0.01% 480
2023
Q4 		$169K Hold
11,300
– – ﹤0.01% 487
2023
Q3 		$146K Hold
11,300
– – ﹤0.01% 492
2023
Q2 		$212K Hold
11,300
– – ﹤0.01% 488
2023
Q1 		$162K Hold
11,300
– – ﹤0.01% 507
2022
Q4 		$213K Hold
11,300
– – ﹤0.01% 491
2022
Q3 		$386K Hold
11,300
– – 0.01% 447
2022
Q2 		$175K Hold
11,300
– – ﹤0.01% 518
2022
Q1 		$274K Buy
+11,300
New +$323K 0.01% 489

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Erste Asset Management's VERV Position: Q4 2024 in Review

Erste Asset Management sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 11,300 shares — an estimated $56.3K sold.

Erste Asset Management first reported a position in VERV in Q1 2022 and held it in 11 quarters. The position peaked at $386K in Q3 2022. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

  • Erste Asset Management reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Erste Asset Management sold 11,300 Verve Therapeutics shares in Q4 2024, an estimated $56.3K.
  • Erste Asset Management first reported a position in Verve Therapeutics in Q1 2022 and held it in 11 quarters.
  • Erste Asset Management's Verve Therapeutics position peaked at $386K in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on Erste Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.